Targets › DKK1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology.
Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6. DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. (UniProt, O94907)
Open in Phaseline: the race on DKK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Royal Marsden NHS Foundation Trust | DKN-01 Dickkopf-related protein 1 inhibitor | DKK1 | Phase 1 | Metastatic Esophageal Cancer | – |
Metastatic Esophageal Cancer (1)
antibody (1)
Royal Marsden NHS Foundation Trust (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.